{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:58:34Z","timestamp":1780441114140,"version":"3.54.1"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848050005"],"award-info":[{"award-number":["848050005"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Biologicals have become a cornerstone in rheumatoid arthritis (RA) treatment. The increased risk of serious infections associated with their use is well-established. Non-serious infections, however, occur more frequently and are associated with a high socioeconomic burden and impact on quality of life but have not received the same attention in the literature to date. The aim of this study was to gain insight into the various non-serious infections reported in RA patients using biologicals and their experienced burden.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>The Dutch Biologic Monitor was a prospective observational study that included adults with rheumatoid arthritis and biological use who answered bimonthly questionnaires on the adverse drug reactions (ADRs) they experienced from their biological and reported the associated impact score (ranging from 1, no impact, to 5, very high impact). ADRs were assigned a MedDRA code by pharmacovigilance experts and labeled as definite, probable, possible or no infection by infectious disease professionals. Descriptive statistics were performed using medians and interquartile ranges.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 586 patients were included in the final analysis. Eighty-five patients (14.5%) reported a total of 421 ADRs labeled as probable or definite infections by the experts. Patient-assigned burden was ADR-specific. Upper respiratory tract infections were most frequently reported and had a high rate of recurrence or persistence, with a median impact score of 3.0 (IQR 2.0\u20133.0) which remained stable over time.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Discussion<\/jats:title>\n<jats:p>Non-serious infections significantly outnumbered serious infections in this real-life cohort of RA patients using biologicals (77.1 non-serious infections and 1.3 serious infections per 100 patient years, respectively). Infections in the upper respiratory tract were rated as having an average burden, which remained constant over a long period of time. Awareness of the impact of recurrent and chronic non-serious infections may enable healthcare professionals to timely treat and maybe even prevent them, which would lessen the associated personal and socioeconomic burden.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0296821","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:25:46Z","timestamp":1708453546000},"page":"e0296821","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Burden of non-serious infections during biological use for rheumatoid arthritis"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9211-5504","authenticated-orcid":true,"given":"Barbara","family":"Bergmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Jessurun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette","family":"van Lint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3661-9035","authenticated-orcid":true,"given":"Jean-Luc","family":"Murk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e8ne","family":"van Puijenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4311-3550","authenticated-orcid":true,"given":"Esther","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"pone.0296821.ref001","article-title":"The Burden of Rheumatoid Arthritis: Findings from the 2019 Global Burden of Diseases Study and Forecasts for 2030 by Bayesian Age-Period-Cohort Analysis.","volume":"12","author":"Y Cai","year":"2023","journal-title":"J Clin Med."},{"key":"pone.0296821.ref002","doi-asserted-by":"crossref","first-page":"2235042X19853484","DOI":"10.1177\/2235042X19853484","article-title":"Morbidity and mortality in patients with rheumatoid arthritis compared with an age- and sex-matched control population: A nationwide register study.","volume":"9:","author":"K L\u00f8ppenthin","year":"2019","journal-title":"J Comorb."},{"issue":"Suppl 3","key":"pone.0296821.ref003","first-page":"iii30","article-title":"Why do people with rheumatoid arthritis still die prematurely?","volume":"3","author":"SE Gabriel","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"pone.0296821.ref004","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","article-title":"Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF\u03b1 inhibitors and rituximab","volume":"74","author":"J Listing","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"pone.0296821.ref005","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40273-014-0174-6","article-title":"The burden of disease in rheumatoid arthritis.","volume":"32","author":"T Uhlig","year":"2014","journal-title":"Pharmacoeconomics."},{"key":"pone.0296821.ref006","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis.","volume":"4","author":"JS Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"pone.0296821.ref007","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1136\/annrheumdis-2018-213289","article-title":"Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry","volume":"77","author":"SA Bergstra","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0296821.ref008","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12325-020-01522-8","article-title":"Epidemiology and Treatment of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis in Germany: A Real-World Evidence Study.","volume":"38","author":"C Grellmann","year":"2021","journal-title":"Adv Ther."},{"issue":"4","key":"pone.0296821.ref009","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.rdc.2012.08.016","article-title":"Nonserious infections: should there be cause for serious concerns?","volume":"38","author":"KH Dao","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"pone.0296821.ref010","first-page":"146:9S","article-title":"Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis and an inadequate response to background methotrexate therapy: results of a phase 3 study.","author":"PC Taylor","year":"2016","journal-title":"Swiss medical weekly."},{"issue":"8","key":"pone.0296821.ref011","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2011-200706","article-title":"Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial","volume":"71","author":"W Stohl","year":"2012","journal-title":"Annals of the rheumatic diseases"},{"issue":"11","key":"pone.0296821.ref012","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1136\/ard.2008.099218","article-title":"The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial","volume":"68","author":"M Schiff","year":"2009","journal-title":"Annals of the rheumatic diseases"},{"issue":"11","key":"pone.0296821.ref013","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"EW St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"10","key":"pone.0296821.ref014","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/art.41754","article-title":"Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.","volume":"73","author":"K Bechman","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"pone.0296821.ref015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003064","article-title":"Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies.","volume":"9","author":"M Aureal","year":"2023","journal-title":"RMD Open."},{"key":"pone.0296821.ref016","article-title":"Infections in Biological and Targeted Synthetic Drug Use in Rheumatoid Arthritis: Where do We Stand? A Scoping Review and Meta-analysis","author":"BJM Bergmans","year":"2023","journal-title":"Rheumatol Ther."},{"issue":"a","key":"pone.0296821.ref017","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12913-016-1620-2","article-title":"The economic burden of urinary tract infections in women visiting general practices in France: a cross-sectional survey.","volume":"16","author":"M Fran\u00e7ois","year":"2016","journal-title":"BMC Health Serv Res."},{"issue":"2","key":"pone.0296821.ref018","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1067\/mda.2003.7","article-title":"Epidemiology of urinary tract infections: incidence, morbidity, and economic costs","volume":"49","author":"B. Foxman","year":"2003","journal-title":"Dis Mon."},{"issue":"2","key":"pone.0296821.ref019","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1378\/chest.122.2.603","article-title":"Economic burden of respiratory infections in an employed population.","volume":"122","author":"HG Birnbaum","year":"2002","journal-title":"Chest."},{"issue":"2","key":"pone.0296821.ref020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4193\/Rhin19.424","article-title":"The socioeconomic cost of chronic rhinosinusitis study.","volume":"58","author":"NW Wahid","year":"2020","journal-title":"Rhinology"},{"issue":"4","key":"pone.0296821.ref021","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archinte.163.4.487","article-title":"The economic burden of non-influenza-related viral respiratory tract infection in the United States","volume":"163","author":"AM Fendrick","year":"2003","journal-title":"Arch Intern Med"},{"issue":"7056","key":"pone.0296821.ref022","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/bmj.313.7056.530","article-title":"Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals","volume":"313","author":"TC Egberts","year":"1996","journal-title":"Bmj"},{"issue":"2","key":"pone.0296821.ref023","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2006.02746.x","article-title":"Patient reporting of suspected adverse drug reactions: a review of published literature and international experience","volume":"63","author":"A Blenkinsopp","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"20","key":"pone.0296821.ref024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15200","article-title":"Evaluation of patient reporting of adverse drug reactions to the UK \u2019Yellow Card Scheme\u2019: literature review, descriptive and qualitative analyses, and questionnaire surveys.","volume":"15","author":"AJ Avery","year":"2011","journal-title":"Health Technol Assess"},{"issue":"11","key":"pone.0296821.ref025","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","article-title":"Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study","volume":"7","author":"E Basch","year":"2006","journal-title":"Lancet Oncol"},{"issue":"1","key":"pone.0296821.ref026","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/rheumatology\/keq300","article-title":"How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician- and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register","volume":"50","author":"L G\u00e4wert","year":"2011","journal-title":"Rheumatology (Oxford)."},{"issue":"23","key":"pone.0296821.ref027","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes","volume":"101","author":"E Basch","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"pone.0296821.ref028","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00002018-200831060-00006","article-title":"Adverse drug reaction reporting by patients in the Netherlands: three years of experience.","volume":"31","author":"J de Langen","year":"2008","journal-title":"Drug Saf."},{"issue":"6","key":"pone.0296821.ref029","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/kez412","article-title":"Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system.","volume":"59","author":"LJ Kosse","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"pone.0296821.ref030","first-page":"140:55","article-title":"A technique for the measurement of attitudes","volume":"22","author":"R. Likert","year":"1932","journal-title":"Archives of Psychology."},{"key":"pone.0296821.ref031","unstructured":"European Medicines Agency. Serious adverse reaction. Available from: https:\/\/www.ema.europa.eu\/en\/glossary\/serious-adverse-reaction."},{"issue":"2","key":"pone.0296821.ref032","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA).","volume":"20","author":"EG Brown","year":"1999","journal-title":"Drug Saf"},{"key":"pone.0296821.ref033","volume-title":"R: A Language and Environment for Statistical Computing.","author":"R Core Team","year":"2021"},{"key":"pone.0296821.ref034","author":"RF Hadley Wickham","year":"2023","journal-title":"dplyr: A Grammar of Data Manipulation"},{"key":"pone.0296821.ref035","author":"D. Comtois","year":"2022","journal-title":"summarytools: Tools to Quickly and Neatly Summarize Data"},{"key":"pone.0296821.ref036","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"H. Wickham","year":"2016"},{"issue":"10","key":"pone.0296821.ref037","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s10067-013-2303-6","article-title":"Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.","volume":"32","author":"P Hor\u00e1k","year":"2013","journal-title":"Clin Rheumatol."},{"issue":"5","key":"pone.0296821.ref038","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/rheumatology\/ket465","article-title":"Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.","volume":"53","author":"H Yamanaka","year":"2014","journal-title":"Rheumatology (Oxford, England)."},{"issue":"19","key":"pone.0296821.ref039","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archinternmed.2009.306","article-title":"Reporting of Safety Results in Published Reports of Randomized Controlled Trials","volume":"169","author":"I Pitrou","year":"2009","journal-title":"Archives of Internal Medicine"},{"issue":"19","key":"pone.0296821.ref040","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archinternmed.2009.313","article-title":"Adverse Events in Randomized Trials: Neglected, Restricted, Distorted, and Silenced","volume":"169","author":"JPA Ioannidis","year":"2009","journal-title":"Archives of Internal Medicine"},{"key":"pone.0296821.ref041","doi-asserted-by":"crossref","first-page":"4s","DOI":"10.1016\/S0002-9343(01)01058-0","article-title":"Epidemiology of viral respiratory infections","volume":"1126A","author":"AS Monto","year":"2002","journal-title":"Am J Med"},{"issue":"2","key":"pone.0296821.ref042","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1249\/MSS.0b013e3181edf108","article-title":"Physical activity, stress, and self-reported upper respiratory tract infection.","volume":"43","author":"E Fondell","year":"2011","journal-title":"Med Sci Sports Exerc"},{"issue":"5","key":"pone.0296821.ref043","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/rheumatology\/kev437","article-title":"Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology\u2019s ORA registry.","volume":"55","author":"C Lahaye","year":"2016","journal-title":"Rheumatology (Oxford, England)."},{"issue":"3","key":"pone.0296821.ref044","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3899\/jrheum.140853","article-title":"Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy","volume":"42","author":"KJ Aaltonen","year":"2015","journal-title":"J Rheumatol"},{"issue":"9","key":"pone.0296821.ref045","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40264-020-00946-z","article-title":"Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases.","volume":"43","author":"JA van Lint","year":"2020","journal-title":"Drug Saf."},{"issue":"5","key":"pone.0296821.ref046","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","article-title":"Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"61","author":"SM Du Pan","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"11","key":"pone.0296821.ref047","doi-asserted-by":"crossref","first-page":"e0241575","DOI":"10.1371\/journal.pone.0241575","article-title":"Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study.","volume":"15","author":"LF Iannone","year":"2020","journal-title":"PLoS One."},{"issue":"2","key":"pone.0296821.ref048","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4104\/pcrj.2012.00011","article-title":"High costs and burden of illness in acute rhinosinusitis: real-life treatment patterns and outcomes in Swedish primary care.","volume":"21","author":"P Stj\u00e4rne","year":"2012","journal-title":"Prim Care Respir J."},{"key":"pone.0296821.ref049","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps.","volume":"14","author":"C Bachert","year":"2021","journal-title":"J Asthma Allergy"},{"issue":"7","key":"pone.0296821.ref050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11882-020-00917-5","article-title":"Common Cold and Acute Rhinosinusitis: Up-to-Date Management in 2020","volume":"20","author":"F Jaume","year":"2020","journal-title":"Curr Allergy Asthma Rep"},{"key":"pone.0296821.ref051","first-page":"S22","article-title":"International Consensus Statement on Allergy and Rhinology: Rhinosinusitis.","volume":"61","author":"RR Orlandi","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4","key":"pone.0296821.ref052","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2500\/ajra.2009.23.3355a","article-title":"Contemporary assessment of the disease burden of sinusitis","volume":"23","author":"N. Bhattacharyya","year":"2009","journal-title":"Am J Rhinol Allergy"},{"issue":"7","key":"pone.0296821.ref053","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/lary.25180","article-title":"Cost of adult chronic rhinosinusitis: A systematic review","volume":"125","author":"KA Smith","year":"2015","journal-title":"Laryngoscope"},{"issue":"1","key":"pone.0296821.ref054","doi-asserted-by":"crossref","first-page":"e018788","DOI":"10.1136\/bmjopen-2017-018788","article-title":"Overuse of diagnostic tools and medications in acute rhinosinusitis in Spain: a population-based study (the PROSINUS study).","volume":"8","author":"F Jaume","year":"2018","journal-title":"BMJ Open"},{"issue":"1","key":"pone.0296821.ref055","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4104\/pcrj.2010.00064","article-title":"Management of rhinosinusitis in Dutch general practice.","volume":"20","author":"R Hoffmans","year":"2011","journal-title":"Prim Care Respir J"},{"issue":"1","key":"pone.0296821.ref056","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40121-014-0054-6","article-title":"Recurrent Lower Urinary Tract Infections Have a Detrimental Effect on Patient Quality of Life: a Prospective, Observational Study.","volume":"4","author":"J Renard","year":"2014","journal-title":"Infect Dis Ther."},{"issue":"1","key":"pone.0296821.ref057","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14737167.2017.1359543","article-title":"Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT).","volume":"18","author":"F Wagenlehner","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"pone.0296821.ref058","first-page":"Doc01","article-title":"Psychosocial burden of recurrent uncomplicated urinary tract infections.","volume":"10","author":"KG Naber","year":"2022","journal-title":"GMS Infect Dis."},{"key":"pone.0296821.ref059","doi-asserted-by":"crossref","first-page":"1756287219832172","DOI":"10.1177\/1756287219832172","article-title":"An introduction to the epidemiology and burden of urinary tract infections","volume":"11","author":"M Medina","year":"2019","journal-title":"Ther Adv Urol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0296821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:26:15Z","timestamp":1708453575000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0296821"}},"subtitle":[],"editor":[{"given":"Sreeram V.","family":"Ramagopalan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0296821","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]}}}